Navidea Biopharmaceuticals

NAVB54

Penny Stock

$0.000.00%$0.00

Penny Stock

NAVB54

$0.00

0.00%$0.00

Penny Stock

Performance History

Key Stats
Open	$0.00
Prev. Close	$0.00
EPS	-0.20
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$100.08K
PE Ratio	-

	LOW	HIGH
Day Range	0.00	0.00
52 Week Range	0.00	0.11

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.20

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals Inc (NAVB) is a biopharmaceutical company that focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company's products are designed to accurately identify and guide treatment decisions in various medical conditions, including cancer and autoimmune diseases.

Navidea Biopharmaceuticals Inc (NAVB) has a rich history in the field of precision diagnostics. The company was founded in 1983 and has since been at the forefront of developing innovative technologies for the detection and visualization of disease biomarkers. With its expertise in molecular imaging, Navidea is able to provide healthcare professionals with valuable tools for early disease detection and personalized medicine.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO
Headquarters: Dublin
Employees: 11
Exchange: NYSE

add Navidea Biopharmaceuticals to watchlist

Keep an eye on Navidea Biopharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Navidea Biopharmaceuticals 's (NAVB) price per share?

The current price per share for Navidea Biopharmaceuticals (NAVB) is $0. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Navidea Biopharmaceuticals (NAVB)?

For Navidea Biopharmaceuticals (NAVB), the 52-week high is $0.11, which is 11.2K% from the current price. The 52-week low is $0, the current price is 900% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Navidea Biopharmaceuticals (NAVB) a growth stock?

Navidea Biopharmaceuticals (NAVB) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Navidea Biopharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Navidea Biopharmaceuticals (NAVB) stock price performance year to date (YTD)?

As of the latest data, Navidea Biopharmaceuticals (NAVB) has a year-to-date price change of -98.15%. Over the past six months, the figure is -98%. Looking at a longer horizon, the five-year price change stands at -99.89%.

help

Is Navidea Biopharmaceuticals (NAVB) a profitable company?

Navidea Biopharmaceuticals (NAVB) has a net income of -$8.61M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.68M% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$10.18M. Furthermore, the EBITDA is -$10.13M.

help

What is the market capitalization of Navidea Biopharmaceuticals (NAVB)?

Navidea Biopharmaceuticals (NAVB) has a market capitalization of $100.08K. The average daily trading volume is 4.04K, indicating the stock's liquidity and investor engagement.